Product Pipeline

RH Nanopharma has developed and continues to develop new formulations of salsalate:

Oral tablets, capsules, and soft gel caps of immediate release salsalate
Liquid formulation of immediate release salsalate
Nanosupsensions of salsalate for Intravenous use in reducing operative pain
Topical gels for soft tissue injury/pain using nanoparticles of salsalate
Ocular nanosuspensions for Dry Eye Disease (DED)
Nanosupension of oral salsalate for immediate relief of pain (first human trial Feb 2018)

Our Mission

RH/Nanopharma is a pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing inflammatory diseases.

News and Events


Rh Nanopharmaceuticals,LLC Is Pleased To Announce That It Has Been Awarded The National Institute Of Health – Heal (Help End Addiction Long-Term) Award Effective Today September 26, 2019.

More Info..


RH Nanopharmacuticals Announces That U.S. FDA Granted Pre-Investigational New Drug Meeting (Pre-Ind) For Salsalate To Be Held On June 28, 2018

More Info..